Athersys June 15th Short Interest Update

Athersys (NASDAQ:ATHX) stated loss of 331,305 shares or 5.8% in the short interest. The short interest registered from 5,757,442 on May 31,2016 to 5,426,137 on June 15,2016. In terms of floated shares, the shorted positions stood at 7.4%. The stock has been averaging 453,465 shares daily in trading and would need 12 days to cover the shorts. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 24th after market close.

Athersys (NASDAQ:ATHX): The stock opened at $2.00 on Friday but the bulls could not build on the opening and the stock topped out at $2.00 for the day. The stock traded down to $1.80 during the day, due to lack of any buying support eventually closed down at $1.97 with a loss of -1.75% for the day. The stock had closed at $2.00 on the previous day. The total traded volume was 8,137,414 shares.

The company shares have rallied 66.95% from its 1 Year high price. On Mar 23, 2016, the shares registered one year high at $2.90 and the one year low was seen on Oct 21, 2015. The 50-Day Moving Average price is $2.25 and the 200 Day Moving Average price is recorded at $1.84.

Athersys (NASDAQ:ATHX) has tumbled 9.03% during the past week and has dropped 14.19% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 7.52%. Athersys (NASDAQ:ATHX) has underperformed the index by 11.6% in the last 4 weeks. Investors should watch out for further signals and trade with caution.

Athersys Inc. is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Companys MultiStem cell therapy is being evaluated in multiple clinical trials. Its current clinical development programs are focused on treating inflammatory and immune disorders, neurological conditions, cardiovascular disease and other conditions. It is also identifying and developing small molecule compounds with applications in indications, such as obesity, related metabolic conditions and neurological conditions. It is engaged in the preparation stages for clinical studies in other targeted areas, including the treatment of ARDS. Its current programs include Ischemic Stroke, Acute Myocardial Infarction, Acute Respiratory Distress Syndrome, Hematopoietic Stem Cell Transplant/GvHD and Inflammatory Bowel Disease. In addition to the programs, it is also conducting or supporting clinical activity in other areas, such as solid organ transplant.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *